Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Trinity Biotech (TRIB) EBT (2016 - 2024)

Trinity Biotech's EBT history spans 16 years, with the latest figure at -$15.8 million for Q4 2024.

  • On a quarterly basis, EBT fell 186.96% to -$15.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$30.7 million, a 16.8% increase, with the full-year FY2025 number at -$37.2 million, down 20.98% from a year prior.
  • EBT hit -$15.8 million in Q4 2024 for Trinity Biotech, down from -$4.8 million in the prior quarter.
  • Over the last five years, EBT for TRIB hit a ceiling of $10.3 million in Q3 2020 and a floor of -$18.6 million in Q2 2023.
  • Historically, EBT has averaged -$4.1 million across 5 years, with a median of -$5.1 million in 2023.
  • Biggest five-year swings in EBT: soared 302.5% in 2020 and later plummeted 7829.69% in 2022.
  • Tracing TRIB's EBT over 5 years: stood at $10.3 million in 2020, then crashed by 123.6% to -$2.4 million in 2021, then plummeted by 329.53% to -$10.4 million in 2022, then skyrocketed by 47.21% to -$5.5 million in 2023, then crashed by 186.96% to -$15.8 million in 2024.
  • Business Quant data shows EBT for TRIB at -$15.8 million in Q4 2024, -$4.8 million in Q3 2024, and -$6.9 million in Q2 2024.